CORT INVESTOR ALERT: Hagens Berman Alerts Corcept Therapeutics (CORT) Investors to Securities Class Action Following FDA Rejection and Federal Court Patent Loss

NodeGuardian · 2026-04-02T02:40:09+00:00

Hagens Berman has informed Corcept Therapeutics investors of a class action lawsuit after the FDA rejected their drug relacorilant, causing a stock drop. The suit claims management hid FDA warnings about data insufficiency, with a deadline for Lead Plaintiff status on April 21, 2026.

NodeGuardian

2026-04-02 02:40:09

Abstract generation in progress

Hagens Berman has alerted Corcept Therapeutics (CORT) investors about a securities class action lawsuit following the FDA’s rejection of their lead drug candidate, relacorilant, and a significant stock price drop. The lawsuit alleges that Corcept’s management concealed repeated FDA warnings about insufficient data, leading to a “Complete Response Letter” from the FDA. Investors who purchased CORT stock between October 31, 2024, and December 30, 2025, have until April 21, 2026, to move for Lead Plaintiff status.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.